期刊文献+

VEGFR-3 siRNA对人结肠癌细胞黏附力和侵袭性的抑制作用 被引量:4

Inhibitory effect of VEGFR-3-targeted siRNA against adherence and invasion of human colon cancer cells
下载PDF
导出
摘要 目的:探讨VEGFR-3对人结肠癌细胞黏附力和侵袭性的影响。方法:构建携靶向VEGFR-3基因siRNA(small interfering RNA)表达载体,转染人结肠癌LoVo细胞,半定量RT-PCR和Western blotting检测转染前后LoVo细胞VEGFR-3 mRNA和蛋白表达的变化,基质-黏附实验检测细胞转染后的黏附能力,细胞侵袭实验检测转染后肿瘤细胞侵袭性的改变。结果:携靶向VEGFR-3基因siRNA的表达载体成功构建,RT-PCR检测转染siRNA后LoVo细胞VEGFR-3 mRNA表达水平降低;Western blotting检测转染siRNA后72 h LoVo细胞VEGFR-3蛋白表达下降,其表达相对值由(1.26±0.19)降至(0.39±0.12)(P<0.05)。转染siRNA 72 h后LoVo细胞的黏附能力显著下降[(0.626±0.047)vs(0.407±0.029),P<0.05];LoVo细胞穿膜细胞数(6.38±3.25)明显低于空白对照组(24.82±3.44)、非特异性对照组(23.58±3.73)(P<0.05)。结论:siRNA能够在LoVo细胞中引发RNA干扰效应,下调VEGFR-3基因的表达,进而抑制LoVo细胞的黏附能力和侵袭性。 Objective : To construct a small interfering RNA (siRNA) expression vector ( psiRNA-VEGFR-3 ) targeting vascular endothelial growth factor receptor 3 (VEGFR-3) and to investigate the effects of VEGFR-3 siRNA on the adherence and invasion of human colon cancer cells. Methods: A siRNA expression vector (psiRNA-VEGFR-3) targeting VEGFR-3 were constructed and was used to transfect LoVo cells via lipofectamine 2000. The mRNA and protein expression of VEGFR-3 were examined after transfection by reverse transcriptase polymerase chain reaction (RT-PCR) and Western blotting, respectively. The tumor adhesion ability was detected by cell-matrix adhesion experiment and the invasion ability of tumor cells was evaluated by millicell chamber model. Results: The VEGFR-3 siRNA expression vector was successfully constructed. The expression of VEGFR-3 mRNA and protein was inhibited after psiRNA-VEGFR-3 transfection. Seven- ty-two hours after psiRNA-VEGFR-3 transfection, Western blotting assay showed that the expression of VEGFR-3 protein was decreased from ( 1.26 ±0.19) to (0.39 ±0.12) (P 〈0.05), the adhesion ability of LoVo cells was also significantly decreased compared with the untransfected group and negative control group (0. 407 ± 0. 029 vs0. 626 ± 0. 047,0. 621 ± 0. 068, P 〈 0. 01 ). The invasion assay demonstrated that the number of LoVo cells penetrating the membrane in the transfection group was significantly lower than those in the untransfected and negative control group (6.38 ± 3.25 vs 24.82 ± 3.44, 23.58 ± 3.73, P 〈 0.05 ). Conclusion : The siRNA of VEGFR-3 gene can effectively inhibit the mRNA and protein expression of VEGFR-3 in LoVo cells, therefore restraining the adhesion and invasion ability of LoVo cells.
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 2008年第6期561-565,共5页 Chinese Journal of Cancer Biotherapy
关键词 RNA干扰 血管内皮生长因子受体-3(VEGFR-3) 结肠癌细胞 黏附能力 侵袭能力 RNA interference vascular endothelial growth factor receptor-3 (VEGFR-3) colon cancer cell adhesion ability invasion ability
  • 相关文献

参考文献17

  • 1Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans [J]. Nature, 1998, 391(6669):806-811.
  • 2贾如江,侯丽艳,张有成,吕志诚.VEGFR-3 siRNA体外对人结肠癌细胞生长的抑制作用[J].世界华人消化杂志,2008,16(16):1797-1801. 被引量:3
  • 3Partanen TA, Alitalo K, Miettinen M. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors[J]. Cancer, 1999, 86( 11 ) : 2406-2412.
  • 4van Iterson V, Leidenius M, von Smitten K, et al. VEGF-D in association with VEGFR-3 promotes nodal metastasis in human invasive lobular breast cancer[J].Am J Clin Pathol, 2007,128 (5) : 759-766.
  • 5张明仪,吴建农,张建新,陈吉祥,张清,谢嵘.VEGFR-3在胃癌细胞中表达的意义[J].肿瘤防治研究,2007,34(1):32-34. 被引量:9
  • 6Roberts N, Kloos B, Cassella M, et al. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph mode and distant metastases than inactivation of VEGFR-2 [J].Cancer Res, 2006, 66(5) : 2650-2657.
  • 7Pytowski B, Goldman J, Persaud K, et al. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody[J]. J Natl Cancer Inst. 2005 ,97 ( 1 ) :14- 21.
  • 8Sithanandam G, Smith GT, Masuda A, et al. Cell cycle activation in lung adenocarcinoma cells by the ErbB3/phosphatidylinositol 3-kinase/Akt pathway [ J ] . Carcinogenesis, 2005,24 ( 10 ) : 1581 - 1592.
  • 9Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis [J]. Proc Natl Acad Sci USA, 2001, 98(20) : 10983-10985.
  • 10Cheng JC, Chou CH, Kuo ML, et al. Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway [ J ]. Oncogene, 2006, 25(53): 7009-7018.

二级参考文献25

共引文献16

同被引文献67

  • 1李志革,宋向群,于起涛,曾爱屏,周达,何剑波,王惠临.Herceptin联合化疗对Her-2过度表达的转移性乳腺癌治疗的初步观察[J].肿瘤防治研究,2006,33(9):673-674. 被引量:2
  • 2黄敏,丁健.抗肿瘤药物新靶点[J].中国处方药,2006(12):10-15. 被引量:9
  • 3Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer [ J ]. Biochim Biophys Acta, 1994, 1198 ( 2-3 ) : 165-184.
  • 4Dean-Colomb W, Esteva FJ. HER-2-positive breast cancer: herceptin and beyond[J]. Eur J Cancer, 2008, 44(18): 2806- 2812.
  • 5Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor,predictive factor, and target for therapy[ J]. Oncologist, 1998, 3 (4) : 237-252.
  • 6Ohrt T, Schwille P. siRNA modifications and sub-cellular localization: a question of intracellular transport [ J ] .? Curt Pharm Des, 2008, 14(34) : 3674-3685.
  • 7Shen Y. Advances in the development of siRNA-based therapeutics for cancer[J]. IDrugs, 2008,11 (8) : 572-578.
  • 8Rubin I, Yarden Y. The basic biology of HER-2 [ J]. Ann Oncol, 2001,12 (Suppl 1) : S3-S8.
  • 9Pritchard KI, Messersmith H, Elavathil L, et al. HER-2 and to-poisomerase Ⅱ as predictors of response to chemotherapy [ J ]. J Clin Oncol, 2008, 26(5): 736-744.
  • 10Konecny G, Fritz M, Untch M, et al. HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer[J]. Breast Cancer Res Treat, 2001, 69( 1 ) : 53-63.

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部